You searched for CNS - Labiotech.eu

AI artificial intelligence dementia alzheimer's

News and Trends 13 Jun 2023

How AI can advance research and treatment of CNS disorders

By Xiao Xu, senior research fellow, Cerevance The combination of large-scale biological datasets and developments in artificial intelligence (AI) has revolutionized our understanding and treatment of central nervous system (CNS) disorders. By leveraging AI’s computational power, researchers have been able to interrogate diverse datasets to provide insights into disease mechanisms, discover novel therapeutic compounds, detect […]

June 13, 2023 - 3 minutesmins - By External Contributor

More News! 14 Nov 2022

Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease

Minoryx Therapeutics and Neuraxpharm Group have announced a strategic alliance for the European rights to a new therapy for rare central nervous system (CNS) disease. The companies have entered into a license agreement for leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD). Under the agreement, Minoryx grants Neuraxpharm […]

November 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 18 Oct 2022

Empyrean Neuroscience launches with $22M to target CNS disorders

Empyrean Neuroscience, Inc. has launched with $22 million in series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company, based in New York City and Cambridge, U.K., is founded on a proprietary platform designed to genetically engineer small molecule therapeutics […]

October 18, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

Research identifies new treatment target for CNS injury and neurological disease

Researchers in Birmingham in the U.K. have identified a potential target for drugs to treat long-term neurological conditions like Alzheimer’s Disease and foster nerve regeneration in central nervous system injuries. The research, published last week in Science Advances, is part of a workstream exploring the signaling pathways that respond to DNA damage, which is seen […]

September 22, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Gate Neurosciences emerges from stealth to tackle CNS diseases

Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate Neurosciences, a U.S. biotech company, was founded in 2019 by a team of neuroscience industry veterans to address the need for more effective treatments for CNS disorders, and to overcome long-standing challenges […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Jul 2022

EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS

EditForce, Inc. has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to research, develop and commercialize potential gene therapy products for a specific target disease related to the central nervous system (CNS) by utilizing EditForce’s pentatricopeptide repeat (PPR) protein platform technology. MTPC and EditForce aim to create potential novel pharmaceuticals for the […]

July 5, 2022 - 2 minutesmins - By Jim Cornall

Interview 25 Oct 2017

What Could RNA Therapies Do for the Treatment of CNS Disorders?

Evelyn chatted with Thomas de Vlaam to find out what his company, Amylon, is working on and how it hopes to change the field fighting CNS disorders. De Vlaam came up with AT-010, a drug candidate for the treatment of Katwijk‘s disease, during his time at ProQR. When it became clear that he had something […]

October 25, 2017 - 3 minutesmins - By Alex Dale

Startup Scout 13 Oct 2017

This French Biotech is Taking On CNS Diseases of the Young and the Elderly

This week we’re in Castres in the South of France to visit Neurolixis. This biotech is taking on diseases of the CNS, such as Parkinson’s, depression and schizophrenia. Mission: Neurolixis is tackling CNS and mood diseases, a number of which lack effective treatment options at the moment. The biotech currently has two candidate drugs undergoing […]

October 13, 2017 - 2 minutesmins - By Alex Dale